EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Treatment Options for IDH-Mutant Malignant Gliomas

Sasha N Swensen, Karl Cristie F Figuracion, Vyshak A Venur, Samuel Emerson, Yolanda D Tseng, Simon S Lo, Ralph P Ermoian, Lia M Halasz

Current Treatment Options in Oncology · 2024

DOI: 10.1007/s11864-024-01280-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2024. Verfasst von Sasha N Swensen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Washington/Fred Hutchinson Cancer Center, 1959 NE Pacific St, Box 356043, Seattle, WA, 98195, USA. ss…. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Mutation, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: As the peak incidence of isocitrate dehydrogenase (IDH)-mutant gliomas is amongst young adults, there is a need to balance tumor control with long term side effects of therapy. Following initial clinical presentation and acquisition of contrasted diagnostic imaging, tissue diagnosis is essential in suspected diffuse glioma. Depending on the location and extent of disease, maximal surgical resection is preferred both for histologic diagnosis and initial therapy. Partial resection or biopsy alone is considered when the tumor cannot be completely resected or if there are clinical reservations regarding a more significant operation. The classification of diffuse glioma has evolved over time, with histopathology and molecular marker status guiding discussions of prognosis and postoperative management. In patients with IDH-mutant grade 2 glioma and low-risk features, observation with active surveillance is generally recommended following a gross total resection. For those with high-risk features, which historically included age > 40 years or subtotal resection, adjuvant chemotherapy and radiation therapy are generally recommended, however decisions for adjuvant therapy pose challenges as many of the landmark historical trials guiding adjuvant therapy were performed prior to the molecularly defined era. This is an area where multiple clinical trials are ongoing and hold promise to inform treatment paradigms, including recent data on the use of IDH-mutant inhibitors in grade 2 tumors with recurrent or residual disease. For IDH-mutant grade 3 and 4 glioma, adjuvant chemotherapy and radiation are recommended for all patients after initial resection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseGliomaMutationBrain NeoplasmsHumansCombined Modality TherapyNeoplasm GradingDisease ManagementTreatment OutcomePrognosisClinical Decision-Making

Stichwörter der Autor:innen

1p/19q codeletionAstrocytomaChemotherapyIDH-mutationOligodendrogliomaRadiotherapy

Substanzen

Isocitrate Dehydrogenase

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Washington/Fred Hutchinson Cancer Center, 1959 NE Pacific St, Box 356043, Seattle, WA, 98195, USA. sswensen@uw.edu.
  • Department of Radiation Oncology, University of Washington/Fred Hutchinson Cancer Center, 1959 NE Pacific St, Box 356043, Seattle, WA, 98195, USA.
  • Division of Medical Oncology, Department of Medicine/Fred Hutchinson Cancer Center, University of Washington, 1959 NE Pacific St, Box 356182, Seattle, WA, 98195, USA.
  • Department of Neurological Surgery, University of Washington, 1959 NE Pacific St, Box 356470, Seattle, WA, 98195, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Swensen, S. N., Figuracion, K. C. F., Venur, V. A., Emerson, S., Tseng, Y. D., Lo, S. S., Ermoian, R. P., & Halasz, L. M. (2024). Treatment Options for IDH-Mutant Malignant Gliomas. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01280-7

Vancouver

Swensen SN, Figuracion KCF, Venur VA, Emerson S, Tseng YD, Lo SS, et al. Treatment Options for IDH-Mutant Malignant Gliomas. Current Treatment Options in Oncology. 2024. doi:10.1007/s11864-024-01280-7

BibTeX
@article{Swensen2024,
  author = {Swensen, Sasha N and Figuracion, Karl Cristie F and Venur, Vyshak A and Emerson, Samuel and Tseng, Yolanda D and Lo, Simon S and Ermoian, Ralph P and Halasz, Lia M},
  title = {Treatment Options for IDH-Mutant Malignant Gliomas},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  doi = {10.1007/s11864-024-01280-7}
}
Kostenlos starten →